Clinical Trial Update: A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study evaluating the safety and efficacy of CP-690,550 (tofacitinib) as induction therapy in moderate to severe Crohn's disease; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-04-28